Official Title
A Registry Study of Patients Hospitalized With Confirmed COVID-19
Brief Summary

The design of this registered study aims to evaluate the efficacy and safety of Paxlovidin the treatment of hospitalized COVID-19 patients, and to explore factors related to theefficacy and safety of Paxlovid.

Detailed Description

Not Provided

Not yet recruiting
COVID-19

Drug: paxlovid

Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be
included in this group. Patients treated with PAXLOVID will be included in this group.
This study is a non-interventional observational study, and no intervention measures were
applied to the clinical diagnosis and treatment process of hospitalized COVID-19
patients. The use of Paxlovid is completely decided by the clinical doctors based on the
patients' condition and clinical experience.
Other Name: paxlovid within initial 5 days

Drug: No paxlovid

Patients not treated with PAXLOVID will be included in this group. This study is a
non-interventional observational study, and no intervention measures were applied to the
clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of
Paxlovid is completely decided by the clinical doctors based on the patients' condition
and clinical experience.

Drug: Paxlovid

Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with
covid-19 will be included in this group.
Other Name: Paxlovid outside of the initial 5 days

Eligibility Criteria

Inclusion Criteria:

1. Confirmed diagnosis of COVID-19 infection.

2. Presence of at least one high-risk factor, including age ≥60 years, diabetes,
hypertension, cardiovascular disease, stroke, chronic liver or kidney disease,
cancer, history of smoking or obesity.

Exclusion Criteria:

- No specific exclusion criteria in this study.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Locations

Not Provided

Contacts

Yi Zhang, PhD
+86 01085231464
jeffzhang1619@outlook.com

Beijing Chao Yang Hospital
NCT Number
Keywords
Hospitalized
Paxlovid
MeSH Terms
COVID-19
Nirmatrelvir and ritonavir drug combination